21.02.2020 | Tracker

HCPs excited for Erleada label expansion in prostate cancer

By Laura McIntyre

HCPs excited for Erleada label expansion in prostate cancer

Janssen’s Erleada (apalutamide) approval for expanded use in patients with metastatic hormone-sensitive prostate cancer sparked excitement last month among healthcare professionals (HCP) online. They shared the news on social media often linking to Janssen’s press release on Business Wire. In total, Erleada’s approval was mentioned 34 times.

The second most mentioned product, relating to its EMA approval, was a conditional marketing authorization for Roche’s Polivy (polatuzumab vedotin), in combination with rituximab and bendamustine for treating patients with relapsed or refractory diffuse large B-cell lymphoma. Graham Collins, a lymphoma specialist in the Oxford Cancer and Haematology Centre, wondered how it will perform in the NICE appraisal process.

Besides the various medicines discussed, cardiologists also enthusiastically posted about Abbott’s world first transcatheter mitral valve, Tendyne. HCPs shared news of its approval, sharing the article by Diagnostic and Interventional Cardiology and reposting Abbott’s tweet.

We are tracking the HCP reaction to EMA approvals and related topics each month. You can keep up to date with this and other pharmaceutical tracking updates, including FDA drug approvals, within the Tracking section of CREATION Knowledge or by signing up our monthly newsletter.


EMA Approvals tracker: HCPs anticipating 2020 approvals

Methodology notes:

  • Data for this research was analysed from the online Twitter conversations of HCPs talking about EMA approvals in English language (all other languages are available), between 15 January and 14 February, 2020.
  • Between 15 January and 14 February, 2020, 84 HCPs posted relating to EMA approvals 89 times all over the world.

View all articles >

Meet the Author

Laura McIntyre

Suggested next

16.03.2022 | Article

HCPs discuss novel treatments as they meet back in person at ASCO GU 2022

HCPs discuss novel treatments as they meet back in person at ASCO GU 2022...

By Mark Sullivan

21.06.2022 | Article

Learn what was important to HCPs at ASCO 2022

ASCO provides a great platform for HCPs to hear about the latest developments in the oncolog

By Laura Marsh

View all articles >